


The Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1. -22. (Canceled)

23. (Previously presented) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond, $(CH_2)_n$, O, S, or $O(CH_2)_n$,

wherein n=1-6;

$R_1=C_{1-6}$ alkyl, optionally substituted with OH or NH_2 ;


$R_2=F$ or $COOR_5$,

wherein R_5 is C_{1-6} alkyl, optionally substituted with OH or NH_2 ;

$R_3=CH_3$ or $(CH_2)_n-COOR_6$,

wherein n=1-6 and R_6 is C_{1-6} alkyl, optionally substituted with OH or NH_2 ;

$R_4=(CH_2)_n-COR_7R_8$, $-(CH_2)_n-R_{10}R_{11}$ or



$R_7=O$, NH , or NR_9 ,

$R_8=$ optionally substituted aryl or heterocycle,

$R_9=C_{1-6}$ alkyl,

$R_{10}=O$, S, SO , SO_2 , NH , or NR_{12} ,

$R_{11}=$ aryl or heterocyclyl optionally substituted with $(CH_2)_nCOOR_{14}$,

$R_{12}=C_{1-6}$ alkyl, optionally substituted with OH or NH₂,

$R_{13}=C_{1-6}$ alkyl, optionally substituted with OH or NH₂,


$R_{14}=C_{1-6}$ alkyl, optionally substituted with OH or NH₂,

$R_{15}=(CH_2)_nCOOR_{16}$,

$R_{16}=C_{1-6}$ alkyl, optionally substituted with OH or NH₂,


R_{17} =not present or COOR₁₈ wherein R₁₈ is C₁₋₆ alkyl, optionally substituted with OH or NH₂, and wherein n=1-6.

24. (Previously presented) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has a formula selected from the group consisting of:




X=bond, CH₂, or OCH₂

R=lower alkyl optionally substituted OH or NH₂;




R=lower alkyl optionally substituted by OH or NH₂;




n=1 to 3

R=lower alkyl optionally substituted by OH or NH₂;




n=1 to 3

R=lower alkyl optionally substituted by OH or NH₂;




R=lower alkyl optionally substituted by OH or NH₂;



n=1 to 3 X=O, NH, NR where R is lower alkyl

Y=optionsubstituted aryl or heterocyclyl; and




n=0 to 2

X=O, S, SO, SO₂, NH NR or N(CH₂)_mCOOH where m is 0 or 2

Y=aryl or heterocyclyl substituted with (CH₂)_mCOOH where m is 0 to 2.


25. (Original) The compound, according to claim 24, wherein said compound has the following structure:



X=bond, CH₂, or OCH₂


R=lower alkyl optionally substituted OH or NH₂.

26. (Original) The compound, according to claim 24, wherein said compound has the following structure:



R=lower alkyl optionally substituted by OH or NH₂.


27. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH₂.


28. (Original) The compound, according to claim 24, wherein said compound has the following structure:



n=1 to 3

R=lower alkyl optionally substituted by OH or NH₂.

29. (Original) The compound, according to claim 24, wherein said compound has the following structure:




R=lower alkyl optionally substituted by OH or NH₂.

30. – 31. (Canceled)

32. (Previously Presented) The method, according to claim 23, wherein the patient is a human.

33. (Previously Presented) The method, according to claim 23, wherein said method is used to treat a condition selected from the group consisting of hypertension, angina, ischemia, arrhythmia, congestive heart failure, and cardiac insufficiency.

34. (Currently Amended) A method for blocking a calcium channel in a patient in need of such blocking wherein said method comprises administering to said patient a calcium channel blocking compound wherein said compound has the following structure:



wherein:

X=a bond, (CH₂)_n, O, S, or O(CH₂)_n,

wherein n=1-6;

R₁=C₁₋₆ alkyl, optionally substituted with OH or NH₂;


R₂=F or COOR₅,

wherein R₅ is C₁₋₆ alkyl, optionally substituted with OH or NH₂;

R₃=CH₃ or (CH₂)_n--COOR₆,

wherein n=1-6 and R₆ is C₁₋₆ alkyl, optionally substituted with OH or NH₂;

R₄=(CH₂)_n--COR₇R₈, --(CH₂)_n--R₁₀R₁₁ or



$R_7=O, NH,$ or $NR_9,$

$R_8=$ optionally substituted aryl or heterocycle,

$R_9=C_{1-6}$ alkyl,

$R_{10}=O, S, SO, SO_2, NH,$ or $NR_{12},$

$R_{11}=$ aryl or heterocycl Y l optionally substituted with $(CH_2)_nCOOR_{14},$

$R_{12}=C_{1-6}$ alkyl, optionally substituted with OH or $NH_2,$

$R_{13}=C_{1-6}$ alkyl, optionally substituted with OH or $NH_2,$

$R_{14}=C_{1-6}$ alkyl, optionally substituted with OH or $NH_2,$

$R_{15}=$ is H,

$R_{17}=$ not present or $COOR_{18}$ wherein R_{18} is C_{1-6} alkyl, optionally substituted with OH or $NH_2,$ and
wherein $n=1-6.$ $n=1-6;$

provided that when R_2 is fluoro; X is O; R_3 is methyl, $-(CH_2)_{0-1}OR_1$ is $-(CH_2)-O-C_{1-6}$ alkyl;

